5 results match your criteria: "Imperial College Healthcare NHS Trust St Mary's Hospital[Affiliation]"
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
AIDS Res Ther
September 2016
Clinical Trials, Faculty of Medicine, Winston Churchill Wing, St. Mary's Hospital, Imperial College, Praed Street, London, W2 1NY UK ; Department of HIV and Genitourinary Medicine, Imperial College Healthcare NHS Trust St Mary's Hospital, London, UK.
Background: Cognitive function is reported to improve after the initiation of combination antiretroviral therapy (cART). Data on the evolution of such changes are limited. We assessed the dynamics of changes in cognitive parameters, in HIV-positive subjects initiating cART.
View Article and Find Full Text PDFMedical Errors in IR: Where Are We? A Systematic Review.
J Vasc Interv Radiol
November 2015
Department of Surgery and Cancer Imperial College London, London, United Kingdom; Department of Interventional Radiology Imperial College Healthcare NHS Trust St Mary's Hospital, 3rd floor QEQM building, Praed Street, London W21NY, United Kingdom.
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers.
J Antimicrob Chemother
February 2016
Imperial College, Faculty of Medicine, London, UK Department of HIV and Genitourinary Medicine, Imperial College Healthcare NHS Trust St Mary's Hospital, London, UK.
Objectives: Boceprevir is a first-generation direct-acting antiviral licensed for the treatment of hepatitis C infection. Sildenafil is an oral therapy for erectile dysfunction. As boceprevir is a potent inhibitor of CYP3A4, potential pharmacokinetic interactions may occur when it is coadministered with sildenafil.
View Article and Find Full Text PDFSimulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.
J Int AIDS Soc
January 2016
Department of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK.
Introduction: Treatment of HIV/TB co-infection is challenging due to high drug-drug interaction potential between antiretrovirals and rifamycins, such as rifampicin (RIF). The PK interaction between darunavir/ritonavir (DRV/RTV) and RIF has not been studied. Utilizing other protease inhibitor data, population PK modelling and simulation was applied to assess the impact of RIF on DRV/RTV PK and generate alternative dosing strategies to aid future clinical trial design.
View Article and Find Full Text PDFRilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
J Antimicrob Chemother
June 2014
Faculty of Medicine, Imperial College, London, UK Department of HIV and Genitourinary Medicine, Imperial College Healthcare NHS Trust St Mary's Hospital, London, UK.
Objectives: Pharmacokinetic parameters following modifications to antiretroviral therapy and sanctuary site exposure are often unknown for recently licensed antiretrovirals. We assessed plasma, CSF and seminal plasma (SP) exposure of rilpivirine after switching from nevirapine.
Methods: HIV-infected male subjects receiving tenofovir/emtricitabine/nevirapine (245/200/400 mg) once daily switched to tenofovir/emtricitabine/rilpivirine (245/200/25 mg) once daily for 60 days when CSF and semen samples were collected.